# Endurant Evo US Clinical Trial

Study · id `cardio:ct-nct02393716` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02393716](<https://clinicaltrials.gov/study/NCT02393716>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT02393716

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 139 participants.

## Technical summary

Registry record NCT02393716. Allocation not applicable; no masking; primary purpose treatment. Start 2015-04 (actual); primary completion 2021-06-25 (actual). Results posted on 2022-12-06.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 139 participants (enrolled count; ClinicalTrials.gov record NCT02393716, source copy `cardio:ctgov-nct02393716-2022-12-06`, retrieved 2026-11-18)
- Started: 2015-04 (actual) (ClinicalTrials.gov record NCT02393716, source copy `cardio:ctgov-nct02393716-2022-12-06`, retrieved 2026-11-18)
- Primary completion: 2021-06-25 (actual) (ClinicalTrials.gov record NCT02393716, source copy `cardio:ctgov-nct02393716-2022-12-06`, retrieved 2026-11-18)
- Completion: 2021-06-25 (actual) (ClinicalTrials.gov record NCT02393716, source copy `cardio:ctgov-nct02393716-2022-12-06`, retrieved 2026-11-18)
- Results first posted: 2022-12-06 (ClinicalTrials.gov record NCT02393716, source copy `cardio:ctgov-nct02393716-2022-12-06`, retrieved 2026-11-18)
- Countries: United States (ClinicalTrials.gov record NCT02393716, source copy `cardio:ctgov-nct02393716-2022-12-06`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02393716-2022-12-06`, retrieved 2026-11-18)

## The registry's words

- Brief title: Endurant Evo US Clinical Trial
- Condition: Abdominal Aortic Aneurysm
- Condition: AAA
- Intervention (Device): Endurant Evo AAA Stent Graft System
- Intervention (Procedure): Endovascular aneurysm repair (EVAR)
- Lead sponsor: Medtronic Cardiovascular
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Abdominal aortic aneurysm (`cardio:abdominal-aortic-aneurysm`)
- Registry condition terms include this condition: Aortic aneurysm (`cardio:aortic-aneurysm`)
- Registry lists this organization as the lead sponsor: Medtronic (`cardio:medtronic`)

## Provenance

Content hash: cdaaf2d8d140a8a86631762b66ce6639c790fc9161b49e6979ee09a81aeecaf9
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
